Loading…
Imaging performance in guiding response to neoadjuvant therapy according to breast cancer subtypes: A systematic literature review
Highlights • 15 observational studies examined imaging performance for measuring response during NAC. • Evidence to conclude on the preferred imaging technique per BC subtype is lacking. •18 FDG-PET/CT seems to be preferred in ER-negative/HER2positive BC over MRI. • MRI and18 FDG-PET/CT are promisin...
Saved in:
Published in: | Critical reviews in oncology/hematology 2017-04, Vol.112, p.198-207 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c479t-25968497805b4faafb110041c7a079cbbff86b3348c4868fcd3dc787c2c37d493 |
---|---|
cites | cdi_FETCH-LOGICAL-c479t-25968497805b4faafb110041c7a079cbbff86b3348c4868fcd3dc787c2c37d493 |
container_end_page | 207 |
container_issue | |
container_start_page | 198 |
container_title | Critical reviews in oncology/hematology |
container_volume | 112 |
creator | Lindenberg, Melanie A Miquel-Cases, Anna Retèl, Valesca P Sonke, Gabe S Wesseling, Jelle Stokkel, Marcel P.M van Harten, Wim H |
description | Highlights • 15 observational studies examined imaging performance for measuring response during NAC. • Evidence to conclude on the preferred imaging technique per BC subtype is lacking. •18 FDG-PET/CT seems to be preferred in ER-negative/HER2positive BC over MRI. • MRI and18 FDG-PET/CT are promising in both triple negative and HER2-positive BC. • Consensus should be reached on: interval time, cut-off values, and pCR definitions. |
doi_str_mv | 10.1016/j.critrevonc.2017.02.014 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1880080019</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1040842817300823</els_id><sourcerecordid>1880080019</sourcerecordid><originalsourceid>FETCH-LOGICAL-c479t-25968497805b4faafb110041c7a079cbbff86b3348c4868fcd3dc787c2c37d493</originalsourceid><addsrcrecordid>eNqNUk1v1DAUjBCIfsBfQD5ySbAdb-xwQCoV0EqVOLScLeflZXFI4mA7W-XaX47DFpB6QrJky5qZp5l5WUYYLRhl1bu-AG-jx4OboOCUyYLygjLxLDtlStY5FRV7nt5U0FwJrk6ysxB6SqkQlXyZnXBV8h2v6Gn2cD2avZ32ZEbfOT-aCZDYiewX227fHsPspoAkOjKhM22_HMwUSfyO3swrMQDO_0YmQOPRhEhgE_EkLE1cZwzvyQUJa4g4mmiBDDYmalw8JvGDxftX2YvODAFfP97n2bfPn-4ur_Kbr1-uLy9uchCyjjnf1ZUStVR014jOmK5hLBliIA2VNTRN16mqKUuhQKhKddCWLUglgUMpW1GX59nbo-7s3c8FQ9SjDYDDYJKxJWimFKXpsA2qjlDwLgSPnZ69HY1fNaN6a0D3-l8DemtAU65TA4n65nHK0ozY_iX-iTwBPh4BmLwm_14HsJgSa61HiLp19n-mfHgiAoOdLJjhB64Yerf4KWWpmQ6JoG-3TdgWgckyeeRl-Qtp37S4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1880080019</pqid></control><display><type>article</type><title>Imaging performance in guiding response to neoadjuvant therapy according to breast cancer subtypes: A systematic literature review</title><source>ScienceDirect Freedom Collection</source><creator>Lindenberg, Melanie A ; Miquel-Cases, Anna ; Retèl, Valesca P ; Sonke, Gabe S ; Wesseling, Jelle ; Stokkel, Marcel P.M ; van Harten, Wim H</creator><creatorcontrib>Lindenberg, Melanie A ; Miquel-Cases, Anna ; Retèl, Valesca P ; Sonke, Gabe S ; Wesseling, Jelle ; Stokkel, Marcel P.M ; van Harten, Wim H</creatorcontrib><description>Highlights • 15 observational studies examined imaging performance for measuring response during NAC. • Evidence to conclude on the preferred imaging technique per BC subtype is lacking. •18 FDG-PET/CT seems to be preferred in ER-negative/HER2positive BC over MRI. • MRI and18 FDG-PET/CT are promising in both triple negative and HER2-positive BC. • Consensus should be reached on: interval time, cut-off values, and pCR definitions.</description><identifier>ISSN: 1040-8428</identifier><identifier>EISSN: 1879-0461</identifier><identifier>DOI: 10.1016/j.critrevonc.2017.02.014</identifier><identifier>PMID: 28325260</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Antineoplastic Agents - therapeutic use ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Chemotherapy, Adjuvant ; Diagnostic Imaging - methods ; Female ; Hematology, Oncology and Palliative Medicine ; HER2 ; Humans ; Imaging ; Neoadjuvant therapy ; Neoadjuvant Therapy - methods ; Therapeutic response ; Treatment Outcome</subject><ispartof>Critical reviews in oncology/hematology, 2017-04, Vol.112, p.198-207</ispartof><rights>Elsevier B.V.</rights><rights>2017 Elsevier B.V.</rights><rights>Copyright © 2017 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c479t-25968497805b4faafb110041c7a079cbbff86b3348c4868fcd3dc787c2c37d493</citedby><cites>FETCH-LOGICAL-c479t-25968497805b4faafb110041c7a079cbbff86b3348c4868fcd3dc787c2c37d493</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28325260$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lindenberg, Melanie A</creatorcontrib><creatorcontrib>Miquel-Cases, Anna</creatorcontrib><creatorcontrib>Retèl, Valesca P</creatorcontrib><creatorcontrib>Sonke, Gabe S</creatorcontrib><creatorcontrib>Wesseling, Jelle</creatorcontrib><creatorcontrib>Stokkel, Marcel P.M</creatorcontrib><creatorcontrib>van Harten, Wim H</creatorcontrib><title>Imaging performance in guiding response to neoadjuvant therapy according to breast cancer subtypes: A systematic literature review</title><title>Critical reviews in oncology/hematology</title><addtitle>Crit Rev Oncol Hematol</addtitle><description>Highlights • 15 observational studies examined imaging performance for measuring response during NAC. • Evidence to conclude on the preferred imaging technique per BC subtype is lacking. •18 FDG-PET/CT seems to be preferred in ER-negative/HER2positive BC over MRI. • MRI and18 FDG-PET/CT are promising in both triple negative and HER2-positive BC. • Consensus should be reached on: interval time, cut-off values, and pCR definitions.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Chemotherapy, Adjuvant</subject><subject>Diagnostic Imaging - methods</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>HER2</subject><subject>Humans</subject><subject>Imaging</subject><subject>Neoadjuvant therapy</subject><subject>Neoadjuvant Therapy - methods</subject><subject>Therapeutic response</subject><subject>Treatment Outcome</subject><issn>1040-8428</issn><issn>1879-0461</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqNUk1v1DAUjBCIfsBfQD5ySbAdb-xwQCoV0EqVOLScLeflZXFI4mA7W-XaX47DFpB6QrJky5qZp5l5WUYYLRhl1bu-AG-jx4OboOCUyYLygjLxLDtlStY5FRV7nt5U0FwJrk6ysxB6SqkQlXyZnXBV8h2v6Gn2cD2avZ32ZEbfOT-aCZDYiewX227fHsPspoAkOjKhM22_HMwUSfyO3swrMQDO_0YmQOPRhEhgE_EkLE1cZwzvyQUJa4g4mmiBDDYmalw8JvGDxftX2YvODAFfP97n2bfPn-4ur_Kbr1-uLy9uchCyjjnf1ZUStVR014jOmK5hLBliIA2VNTRN16mqKUuhQKhKddCWLUglgUMpW1GX59nbo-7s3c8FQ9SjDYDDYJKxJWimFKXpsA2qjlDwLgSPnZ69HY1fNaN6a0D3-l8DemtAU65TA4n65nHK0ozY_iX-iTwBPh4BmLwm_14HsJgSa61HiLp19n-mfHgiAoOdLJjhB64Yerf4KWWpmQ6JoG-3TdgWgckyeeRl-Qtp37S4</recordid><startdate>20170401</startdate><enddate>20170401</enddate><creator>Lindenberg, Melanie A</creator><creator>Miquel-Cases, Anna</creator><creator>Retèl, Valesca P</creator><creator>Sonke, Gabe S</creator><creator>Wesseling, Jelle</creator><creator>Stokkel, Marcel P.M</creator><creator>van Harten, Wim H</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170401</creationdate><title>Imaging performance in guiding response to neoadjuvant therapy according to breast cancer subtypes: A systematic literature review</title><author>Lindenberg, Melanie A ; Miquel-Cases, Anna ; Retèl, Valesca P ; Sonke, Gabe S ; Wesseling, Jelle ; Stokkel, Marcel P.M ; van Harten, Wim H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c479t-25968497805b4faafb110041c7a079cbbff86b3348c4868fcd3dc787c2c37d493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Chemotherapy, Adjuvant</topic><topic>Diagnostic Imaging - methods</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>HER2</topic><topic>Humans</topic><topic>Imaging</topic><topic>Neoadjuvant therapy</topic><topic>Neoadjuvant Therapy - methods</topic><topic>Therapeutic response</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lindenberg, Melanie A</creatorcontrib><creatorcontrib>Miquel-Cases, Anna</creatorcontrib><creatorcontrib>Retèl, Valesca P</creatorcontrib><creatorcontrib>Sonke, Gabe S</creatorcontrib><creatorcontrib>Wesseling, Jelle</creatorcontrib><creatorcontrib>Stokkel, Marcel P.M</creatorcontrib><creatorcontrib>van Harten, Wim H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Critical reviews in oncology/hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lindenberg, Melanie A</au><au>Miquel-Cases, Anna</au><au>Retèl, Valesca P</au><au>Sonke, Gabe S</au><au>Wesseling, Jelle</au><au>Stokkel, Marcel P.M</au><au>van Harten, Wim H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Imaging performance in guiding response to neoadjuvant therapy according to breast cancer subtypes: A systematic literature review</atitle><jtitle>Critical reviews in oncology/hematology</jtitle><addtitle>Crit Rev Oncol Hematol</addtitle><date>2017-04-01</date><risdate>2017</risdate><volume>112</volume><spage>198</spage><epage>207</epage><pages>198-207</pages><issn>1040-8428</issn><eissn>1879-0461</eissn><abstract>Highlights • 15 observational studies examined imaging performance for measuring response during NAC. • Evidence to conclude on the preferred imaging technique per BC subtype is lacking. •18 FDG-PET/CT seems to be preferred in ER-negative/HER2positive BC over MRI. • MRI and18 FDG-PET/CT are promising in both triple negative and HER2-positive BC. • Consensus should be reached on: interval time, cut-off values, and pCR definitions.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>28325260</pmid><doi>10.1016/j.critrevonc.2017.02.014</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1040-8428 |
ispartof | Critical reviews in oncology/hematology, 2017-04, Vol.112, p.198-207 |
issn | 1040-8428 1879-0461 |
language | eng |
recordid | cdi_proquest_miscellaneous_1880080019 |
source | ScienceDirect Freedom Collection |
subjects | Antineoplastic Agents - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Chemotherapy, Adjuvant Diagnostic Imaging - methods Female Hematology, Oncology and Palliative Medicine HER2 Humans Imaging Neoadjuvant therapy Neoadjuvant Therapy - methods Therapeutic response Treatment Outcome |
title | Imaging performance in guiding response to neoadjuvant therapy according to breast cancer subtypes: A systematic literature review |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T14%3A03%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Imaging%20performance%20in%20guiding%20response%20to%20neoadjuvant%20therapy%20according%20to%20breast%20cancer%20subtypes:%20A%20systematic%20literature%20review&rft.jtitle=Critical%20reviews%20in%20oncology/hematology&rft.au=Lindenberg,%20Melanie%20A&rft.date=2017-04-01&rft.volume=112&rft.spage=198&rft.epage=207&rft.pages=198-207&rft.issn=1040-8428&rft.eissn=1879-0461&rft_id=info:doi/10.1016/j.critrevonc.2017.02.014&rft_dat=%3Cproquest_cross%3E1880080019%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c479t-25968497805b4faafb110041c7a079cbbff86b3348c4868fcd3dc787c2c37d493%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1880080019&rft_id=info:pmid/28325260&rfr_iscdi=true |